Is Avonib reimbursed by medical insurance?

Ivosidenib is a targeted drug developed specifically for cancer patients carrying isocitrate dehydrogenase 1 (IDH1) mutations. It is mainly used to treat specific types of cancer such as acute myeloid leukemia (AML). Ivonib inhibits the activity of IDH1 enzyme and prevents the abnormal metabolism of cancer cells, thereby effectively inhibiting the growth and spread of tumors.

Currently, ivonib has been launched in China, providing a new treatment option for domestic patients. However, this drug has not yet been included in the reimbursement scope of the national medical insurance, so patients need to pay for it when using it. Ivonib is relatively expensive, with monthly treatment costs of about 30,000 to 40,000 yuan. Specific prices may vary by region and hospital, so patients are advised to consult their local hospital pharmacy for accurate information before purchasing.

Compared with the expensive domestic prices, foreign generic drugs, especially the versions from Laos, are much cheaper. The price of generic drugs in Laos is about six to seven thousand yuan, which is far lower than the price of domestic original drugs. Although there is a significant price difference, the ingredients of Lao generic drugs and original drugs are basically the same, and their efficacy has also been widely recognized. Therefore, for patients with limited financial conditions, considering purchasing Laos generic drugs may be a relatively economical option.

In general, ivonib brings new hope to cancer patients with IDH1 mutations. However, due to its high price and not being covered by medical insurance, patients need to fully consider economic factors when choosing treatment options and make decisions under the guidance of professional doctors.